卫信康: 西藏卫信康医药股份有限公司第四届董事会第三次会议决议公告

Meeting Overview - The third meeting of the fourth board of directors of Tibet Weixin Kang Pharmaceutical Co., Ltd. was held on August 27, 2025, with all 7 directors present, ensuring compliance with legal and regulatory requirements [1]. Key Resolutions - The board approved the 2025 semi-annual report (full text and summary) with a unanimous vote of 7 in favor [2]. - A proposal to abolish the supervisory board and amend the company's articles of association and related rules was approved, allowing the audit committee to assume the supervisory functions [2][3]. - The board agreed to submit the proposal regarding the abolition of the supervisory board to the shareholders' meeting for approval [2][4]. - The board approved various governance system amendments, with all votes in favor [3][4]. - A proposal to convene the second extraordinary general meeting of shareholders in 2025 was approved, scheduled for September 12, 2025 [4][5].